LAUSR

At the 2017 American Society of Hematology (ASH) meeting partly standards-changing data in the treatment of hematological malignancies were presented. More than 5000 scientific abstracts are submitted each year and more than 3000 abstracts are accepted for oral and poster presentations through an extensive peer review process. In this issue of memo five hematologists summarized their personal highlights in their respective areas of expertise. My personal highlight was the presentation of the MURANO study. The clear superiority of a targeted therapy changes practical behavior with immunechemotherapy having no place in second-line treatment of chronic lymphocytic leukemia (CLL) anymore. Moreover, the authors summarize important data about the combination of venetoclax and ibrutinib. In addition to CLL, reviews about important developments in the treatment of indolent lymphoma, multiple myeloma, CML, and AML are provided in this series. Concerning indolent lymphoma, Dr. Gilles Salles presented a 10-year update of the PRIMA trial, confirming a progression-free survival (PFS) benefit for